Desai, A. K., Li, C., Gupta, P., Dempsey, K., Bhambhani, V., Hopkin, R., … KIshnani, P. S. (2021). Transforming the clinical outcomes in CRIM-negative infantile Pompe disease identified via newborn screening: The benefits of early treatment with enzyme replacement therapy and immune tolerance induction. In Molecular Genetics and Metabolism (Vol. 132, pp. S33–S33). Elsevier BV. https://doi.org/10.1016/j.ymgme.2020.12.062

Desai, Ankit K., Cindy Li, Punita Gupta, Katherine Dempsey, Vikas Bhambhani, Robert Hopkin, Can Ficicioglu, Pranoot Tanpaiboon, William J. Craigen, and Priya S. KIshnani. “Transforming the clinical outcomes in CRIM-negative infantile Pompe disease identified via newborn screening: The benefits of early treatment with enzyme replacement therapy and immune tolerance induction.” In Molecular Genetics and Metabolism, 132:S33–S33. Elsevier BV, 2021. https://doi.org/10.1016/j.ymgme.2020.12.062.

Desai AK, Li C, Gupta P, Dempsey K, Bhambhani V, Hopkin R, et al. Transforming the clinical outcomes in CRIM-negative infantile Pompe disease identified via newborn screening: The benefits of early treatment with enzyme replacement therapy and immune tolerance induction. In: Molecular Genetics and Metabolism. Elsevier BV; 2021. p. S33–S33.

Desai, Ankit K., et al. “Transforming the clinical outcomes in CRIM-negative infantile Pompe disease identified via newborn screening: The benefits of early treatment with enzyme replacement therapy and immune tolerance induction.” Molecular Genetics and Metabolism, vol. 132, no. 2, Elsevier BV, 2021, pp. S33–S33. Crossref, doi:10.1016/j.ymgme.2020.12.062.

Desai AK, Li C, Gupta P, Dempsey K, Bhambhani V, Hopkin R, Ficicioglu C, Tanpaiboon P, Craigen WJ, KIshnani PS. Transforming the clinical outcomes in CRIM-negative infantile Pompe disease identified via newborn screening: The benefits of early treatment with enzyme replacement therapy and immune tolerance induction. Molecular Genetics and Metabolism. Elsevier BV; 2021. p. S33–S33.